Bivalent recombinant respiratory syncytial virus vaccine (Undisclosed novel adjuvant, Jiangsu Recbio Technology)

双价重组呼吸道合胞病毒疫苗（未披露的新型佐剂，江苏瑞科生物）

Report date: 2025/12/11 09:53:55

Base Information

Drug NameBivalent recombinant respiratory syncytial virus vaccine (Undisclosed novel adjuvant, Jiangsu Recbio Technology)

Drug Alias NameREC-625

ClassificationVaccines > Development/production technology > Genetically engineered subunit vaccineVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsRespiratory Syncytial Virus Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesJiangsu Rec-Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Rec-Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsRespiratory Syncytial Virus Infections

Inactive IndicationsN/A

Other Information

ATC CodeN/A